| 0.9987 -0.051 (-4.89%) | 06-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.34 | 1-year : | 1.49 |
| Resists | First : | 1.15 | Second : | 1.27 |
| Pivot price | 1.09 |
|||
| Supports | First : | 0.94 | Second : | 0.79 |
| MAs | MA(5) : | 1.02 |
MA(20) : | 1.08 |
| MA(100) : | 1.06  |
MA(250) : | 1.22 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 9.8 |
D(3) : | 12.4 |
| RSI | RSI(14): 41.4 |
|||
| 52-week | High : | 2.64 | Low : | 0.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ELUT ] has closed above bottom band by 11.1%. Bollinger Bands are 6.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.06 - 1.07 | 1.07 - 1.07 |
| Low: | 0.97 - 0.98 | 0.98 - 0.99 |
| Close: | 0.99 - 1 | 1 - 1.01 |
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Thu, 04 Jun 2026
Despite Elutia's Pullback, Insiders Still Gained US$75k - simplywall.st
Tue, 02 Jun 2026
Elutia (ELUT) director gifts shares and updates trust, HighCape stakes - Stock Titan
Mon, 18 May 2026
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fri, 15 May 2026
Elutia Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:ELUT) 2026-05-15 - Seeking Alpha
Thu, 14 May 2026
Elutia to Present at the 16th Annual LD Micro Invitational May 18th - TMX Newsfile
Thu, 30 Apr 2026
Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 44 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 45.7 (%) |
| Shares Short | 126 (K) |
| Shares Short P.Month | 129 (K) |
| EPS | -0.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.64 |
| Profit Margin | 434.2 % |
| Operating Margin | -167.9 % |
| Return on Assets (ttm) | -23.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 16.2 % |
| Gross Profit (p.s.) | 0.14 |
| Sales Per Share | 0.27 |
| EBITDA (p.s.) | -0.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -1.54 |
| PEG Ratio | 0 |
| Price to Book value | 1.53 |
| Price to Sales | 3.59 |
| Price to Cash Flow | -0.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|